These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34796690)

  • 1. Clustering based on comorbidities in patients with chronic heart failure: an illustration of clinical diversity.
    Uszko-Lencer NHMK; Janssen DJA; Gaffron S; Vanfleteren LEGW; Janssen E; Werter C; Franssen FME; Wouters EFM; Rechberger S; Brunner La Rocca HP; Spruit MA
    ESC Heart Fail; 2022 Feb; 9(1):614-626. PubMed ID: 34796690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical management of chronic heart failure: a perspective based on the latent structure of comorbidities.
    Zheng C; Han L; Tian J; Li J; He H; Han G; Wang K; Yang H; Yan J; Meng B; Han Q; Zhang Y
    ESC Heart Fail; 2022 Feb; 9(1):595-605. PubMed ID: 34779142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction.
    Uijl A; Savarese G; Vaartjes I; Dahlström U; Brugts JJ; Linssen GCM; van Empel V; Brunner-La Rocca HP; Asselbergs FW; Lund LH; Hoes AW; Koudstaal S
    Eur J Heart Fail; 2021 Jun; 23(6):973-982. PubMed ID: 33779119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic clustering of heart failure with preserved ejection fraction reveals different rates of hospitalization.
    Casebeer A; Horter L; Hayden J; Simmons J; Evers T
    J Cardiovasc Med (Hagerstown); 2021 Jan; 22(1):45-52. PubMed ID: 32941326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.
    Ahmad T; Lund LH; Rao P; Ghosh R; Warier P; Vaccaro B; Dahlström U; O'Connor CM; Felker GM; Desai NR
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure with preserved ejection fraction: A clustering approach to a heterogenous syndrome.
    Schrub F; Oger E; Bidaut A; Hage C; Charton M; Daubert JC; Leclercq C; Linde C; Lund L; Donal E
    Arch Cardiovasc Dis; 2020; 113(6-7):381-390. PubMed ID: 32409103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.
    Bhatt AS; Ambrosy AP; Dunning A; DeVore AD; Butler J; Reed S; Voors A; Starling R; Armstrong PW; Ezekowitz JA; Metra M; Hernandez AF; O'Connor CM; Mentz RJ
    Eur J Heart Fail; 2020 Jun; 22(6):1022-1031. PubMed ID: 32212297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Pressure, Congestion and Heart Failure with Preserved Ejection Fraction Among Patients with and Without Type 2 Diabetes Mellitus. A Cluster Analysis Approach from the Observational Registry DICUMAP.
    Arévalo-Lorido JC; Carretero-Gómez J; Aramburu-Bodas O; Grau-Amoros J; Torres-Cortada G; Camafort-Babkowski M
    High Blood Press Cardiovasc Prev; 2020 Oct; 27(5):399-408. PubMed ID: 32770527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.
    Vanfleteren LE; Spruit MA; Groenen M; Gaffron S; van Empel VP; Bruijnzeel PL; Rutten EP; Op 't Roodt J; Wouters EF; Franssen FM
    Am J Respir Crit Care Med; 2013 Apr; 187(7):728-35. PubMed ID: 23392440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidities and their implications in patients with and without type 2 diabetes mellitus and heart failure with preserved ejection fraction. Findings from the rica registry.
    Arévalo-Lorido JC; Carretero-Gómez J; Gómez-Huelgas R; Llácer P; Manzano L; Quesada Simón MA; Roca Villanueva B; González Franco Á; Cepeda JM; Montero Pérez-Barquero M
    Int J Clin Pract; 2021 Jan; 75(1):e13661. PubMed ID: 32770841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the number of comorbidities on cardiac sympathetic derangement in patients with reduced ejection fraction heart failure.
    Bencivenga L; Komici K; Femminella GD; Paolillo S; Gargiulo P; Formisano R; Assante R; Nappi C; Puzone B; Sepe I; Cittadini A; Vitale DF; Ferrara N; Cuocolo A; Filardi PP; Rengo G
    Eur J Intern Med; 2021 Apr; 86():86-90. PubMed ID: 33485737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
    Hahn VS; Knutsdottir H; Luo X; Bedi K; Margulies KB; Haldar SM; Stolina M; Yin J; Khakoo AY; Vaishnav J; Bader JS; Kass DA; Sharma K
    Circulation; 2021 Jan; 143(2):120-134. PubMed ID: 33118835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL).
    Cascino TM; Kittleson MM; Lala A; Stehlik J; Palardy M; Pamboukian SV; Ewald GA; Mountis MM; Horstmanshof DA; Robinson SW; Shah P; Jorde UP; McLean RC; Richards B; Khalatbari S; Spino C; Taddei-Peters WC; Grady KL; Mann DL; Stevenson LW; Stewart GC; Aaronson KD;
    Circ Heart Fail; 2020 May; 13(5):e006858. PubMed ID: 32418478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study.
    Smith DH; Thorp ML; Gurwitz JH; McManus DD; Goldberg RJ; Allen LA; Hsu G; Sung SH; Magid DJ; Go AS
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):333-42. PubMed ID: 23685625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in characteristics and outcomes in heart failure patients referred for end-stage treatment.
    Fluschnik N; Strangl F; Kondziella C; Goßling A; Becher PM; Schrage B; Schnabel RB; Bernadyn J; Bremer W; Grahn H; Bernhardt AM; Reichenspurner H; Rybczynski M; Blankenberg S; Kirchhof P; Magnussen C; Knappe D
    ESC Heart Fail; 2021 Dec; 8(6):5031-5039. PubMed ID: 34486813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clusters of comorbidities in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Hilberg O; Shaker SB; Davidsen JR; Rasmussen F; Bendstrup E
    Respir Med; 2021; 185():106490. PubMed ID: 34130097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 19. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure.
    Kamiya K; Sato Y; Takahashi T; Tsuchihashi-Makaya M; Kotooka N; Ikegame T; Takura T; Yamamoto T; Nagayama M; Goto Y; Makita S; Isobe M
    Circ Heart Fail; 2020 Oct; 13(10):e006798. PubMed ID: 32986957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.